Table 2 Characteristics of patients who underwent allo-HSCT
Patient no. | Disease status | HSCT method | Donor | Conditioning regimen | GVHD prophylaxis | Adverse reactions | Outcome | Causes of death |
|---|---|---|---|---|---|---|---|---|
1 | CR | HLA 5/10 related donor | Sister | TBI/Cy/VP-16 | CsA + MTX + ATG | Recurrence, acute GVHD I, sepsis | Died | Recurrence, sepsis |
2 | PR | HLA5/10 related donor | Brother | TBI/Cy/VP-16 | CsA+MTX+ATG | Acute GVHD III | Survival | – |
3 | CR | HLA10/10 related donor | Sister | TBI/Cy/VP-16 | CsA+MTX+ATG | Pulmonary infection, acute GVHD II | Survival | – |
4 | CR | HLA5/10 related donor | Brother | TBI/Cy/VP16 | CsA+MTX+ATG | Recurrence, multiple organ failure | Died | Recurrence, multiple organ failure |
5 | CR | HLA5/10 related donor | Mother | TBI/Cy/VP-16 | CsA+MTX+ATG | Acute GVHD I | Survival | – |
6 | PR | HLA5/10 related donor | Mother | Bu/Cy/VP-16 | CsA+MTX+ATG | Pulmonary infection, gastrointestinal bleeding | Died | Pulmonary infection, gastrointestinal bleeding |
7 | CR | HLA5/10 related donor | Sister | Bu/Cy/VP-16 | CsA+MTX+ATG | Pulmonary infection | Survival | – |
8 | CR | HLA5/10 related donor | Brother | TBI/Cy/VP-16 | CsA+MTX+ATG | Acute GVHD I, gastrointestinal bleeding | Survival | – |
9 | PR | HLA5/10 related donor | Brother | TBI/Cy/VP-16 | CsA+MTX+ATG | Acute GVHD I | Survival | – |
10 | CR | HLA5/10 related donor | Father | TBI/Cy/VP-16 | CsA+MTX+ATG | Acute GVHD II, pulmonary infection | Survival | – |
11 | CR | HLA5/10 related donor | Father | TBI/Cy/VP-16 | CsA+MTX+ATG | Acute GVHD III, hemorrhagic cystitis | Survival | – |
12 | CR | HLA5/10 related donor | Father | TBI/Cy/VP-16 | CsA+MTX+ATG | – | Survival | – |
13 | PR | HLA5/10 related donor | Father | TBI/Cy/VP-16 | CsA+MTX+ATG | Acute GVHD I, pulmonary infection | Survival | – |